Lung Therapeutics, a pharmaceutical company establishing new treatments for niche drug indications in fibrosis, lung injuries and diseases, announced Tuesday that it raised $14.3 million in a Series B financing.
The capital will support ongoing clinical trials in multiple locations and advance development for Lung Therapeutics' "transformative" drug for fibrosis, LTI-03.
The company has now raised $17 million in outside funding, aside from the $27 million awarded for discovery research and development.
The latest raise was headed by Bios Partners, a life sciences private equity firm out of Dallas and Fort Worth, Texas.